February 12, 2018, USPSTF. We agree with the USPSTF that current evidence is insufficient to assess potential benefits and harms of adding the ankle-brachial index (ABI), high-sensitivity C-reactive protein (hsCRP), or coronary artery calcification (CAC) score to the traditional risk assessments for CVD.
Read More »Medical Care for Adults
The National Center for Health Research reviews important new research as soon as it is published. We cut through the hype regarding various medical treatments to let you know what is proven and what is unknown about the risks and benefits of various treatment options. We do not accept funding from the companies that make medical products, so you can trust that our information is based on science, and not biased by financial ties to the treatments we’re evaluating.
To find the information you need, please use our search box to search for exactly what you are looking for or browse through our various topics on the right. →
Some of these articles were written this year and others were not, however, if they are on our website it means the information is up-to-date. We always scrutinize new research and call the researchers to learn even more. Then we translate it into plain language that everyone can understand.
If you’re looking for more detailed information about cancer, please go to our Cancer Prevention and Treatment website.
If you don’t see what you are looking for on any health topic, please contact us and we will try to get the information you need within a few days.
NCHR Comments on USPSTF Draft Screening Recommendations for Peripheral Artery Disease (PAD)
USPSTF, February 12, 2018. In order to more widely recommend ABI, we need more studies directly evaluating both the efficacy and harms. Most importantly, we encourage the USPSTF to review studies that analyze the accuracy of ABI and its effect on improving health outcomes in asymptomatic PAD patients.
Read More »Irritable Bowel Syndrome Medication: Update on Zelnorm
Irritable bowel syndrome (IBS) is an uncomfortable intestinal problem that affects nearly one in five Americans, most of whom are women. Unfortunately, known treatments only help with IBS symptoms, not the cause. More so, these treatments often have dangerous side effects. How is it that these drugs are still on the market if they are unsafe? The answer is because of a drug development process known as “treatment IND” (Investigational New Drug). The most recent of these treatment INDs involves a medication known as Zelnorm. What are the dangers, and should you take it for your IBS?
Read More »NCHR and WomenHeart Comments on USPSTF Draft Recommendation Statement Cardiovascular Disease Risk: Screening with Electrocardiography (ECG)
Jan 22, 2018, We commend the USPSTF for reviewing the evidence and developing evidence-based recommendations. There is substantial evidence to recommend against screening in low risk adults and is insufficient to support screening in higher risk adults.
Read More »Football and Brain Injuries: What You Need to Know
There are many hidden dangers of contact sports like football, but new rules emphasizing safety over entertainment may help to reduce risks.
Read More »